However, the drug is newer and more research is needed
Tirazepatide (TZT), a dual glucagon-like peptide-1 (GLP-1)and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist may be effective in managing Covid-19-induced hyperglycemia in diabetic and non-diabetic patients
If this feels quite familiar to you, you are not imagining it, and more importantly youre not stuck with it
Important safety considerations include risks of acute pancreatitis, gallbladder disease, and acute kidney injury (particularly from dehydration)
wholesale acquisition costs range from USD 13,000 to USD 16,000, leaving uninsured and Medicare beneficiaries without diabetes exposed to full list prices [2]Kaiser Family Foundation, Employer Health Benefits Survey 2024, kff.org
Retrieved August 25, 2017